Investor Presentaiton

NASH -key take aways R&D investor presentation 21 Semaglutide showed superior NASH resolution and fewer patients showed progression of fibrosis in the phase 2 trial Semaglutide showed improvements in several biomarkers for fibrosis such as ELF and liver stiffness in the phase 2 trial Future development of semaglutide in NASH is being assessed and discussed with regulators NASH: non-alcoholic steatohepatitis; ELF: enhanced liver fibrosis

View entire presentation